DEA Hemp Rule Is Safe For Now, But That May Change

Law360 (June 15, 2018, 3:16 PM EDT) -- Across the country and throughout the internet, sales of wellness products and alternative medicines containing cannabidiol, known as CBD, are skyrocketing. At the same moment, through an innocuous rule change in late 2016, the U.S. Drug Enforcement Administration announced that CBD, even if extracted from industrial hemp, is classified as a Schedule I drug even though CBD extract is not psychoactive or addictive.[1] Recently, the U.S. Court of Appeals for the Ninth Circuit rejected an industry challenge to the DEA rule.

On April 30, 2018, the Ninth Circuit rejected the Hemp Industries Association's challenge to the DEA rule and held that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!